Cargando…

Insights from molecular docking and molecular dynamics on the potential of vitexin as an antagonist candidate against lipopolysaccharide (LPS) for microglial activation in neuroinflammation

BACKGROUND: Neuroinflammation has been identified to be the key player in most neurodegenerative diseases. If neuroinflammation is left to be unresolved, chronic neuroinflammation will be establish. Such situation is due to the overly-activated microglia which have the tendency to secrete an abundan...

Descripción completa

Detalles Bibliográficos
Autores principales: Yahaya, M. A. F., Bakar, A. R. Abu, Stanslas, J., Nordin, N., Zainol, M., Mehat, M. Z.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8178909/
https://www.ncbi.nlm.nih.gov/pubmed/34090414
http://dx.doi.org/10.1186/s12896-021-00697-4
_version_ 1783703670550953984
author Yahaya, M. A. F.
Bakar, A. R. Abu
Stanslas, J.
Nordin, N.
Zainol, M.
Mehat, M. Z.
author_facet Yahaya, M. A. F.
Bakar, A. R. Abu
Stanslas, J.
Nordin, N.
Zainol, M.
Mehat, M. Z.
author_sort Yahaya, M. A. F.
collection PubMed
description BACKGROUND: Neuroinflammation has been identified to be the key player in most neurodegenerative diseases. If neuroinflammation is left to be unresolved, chronic neuroinflammation will be establish. Such situation is due to the overly-activated microglia which have the tendency to secrete an abundance amount of pro-inflammatory cytokines into the neuron microenvironment. The abundance of pro-inflammatory cytokines will later cause toxic and death to neurons. Toll-like receptor 4 (TLR4)/MD-2 complex found on the cell surface of microglia is responsible for the attachment of LPS and activation of nuclear factor-κB (NF-κB) downstream signalling pathway. Albeit vitexin has been shown to possess anti-inflammatory property, however, little is known on its ability to bind at the binding site of TLR4/MD-2 complex of microglia as well as to be an antagonist for LPS. RESULTS: The present study reveals that both vitexin and donepezil are able to bind at the close proximity of LPS binding site located at the TLR4/MD-2 complex with the binding energy of − 4.35 and − 9.14 kcal/mol, respectively. During molecular dynamic simulations, both vitexin and donepezil formed stable complex with TLR4/MD-2 throughout the 100 ns time length with the root mean square deviation (RMSD) values of 2.5 Å and 4.0 Å, respectively. The root mean square fluctuation (RMSF) reveals that both compounds are stable. Interestingly, the radius of gyration (rGyr) for donepezil shows notable fluctuations when compare with vitexin. The MM-GBSA results showed that vitexin has higher binding energy in comparison with donepezil. CONCLUSIONS: Taken together, the findings suggest that vitexin is able to bind at the binding site of TLR4/MD-2 complex with more stability than donepezil throughout the course of 100 ns simulation. Hence, vitexin has the potential to be an antagonist candidate for LPS.
format Online
Article
Text
id pubmed-8178909
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-81789092021-06-07 Insights from molecular docking and molecular dynamics on the potential of vitexin as an antagonist candidate against lipopolysaccharide (LPS) for microglial activation in neuroinflammation Yahaya, M. A. F. Bakar, A. R. Abu Stanslas, J. Nordin, N. Zainol, M. Mehat, M. Z. BMC Biotechnol Research BACKGROUND: Neuroinflammation has been identified to be the key player in most neurodegenerative diseases. If neuroinflammation is left to be unresolved, chronic neuroinflammation will be establish. Such situation is due to the overly-activated microglia which have the tendency to secrete an abundance amount of pro-inflammatory cytokines into the neuron microenvironment. The abundance of pro-inflammatory cytokines will later cause toxic and death to neurons. Toll-like receptor 4 (TLR4)/MD-2 complex found on the cell surface of microglia is responsible for the attachment of LPS and activation of nuclear factor-κB (NF-κB) downstream signalling pathway. Albeit vitexin has been shown to possess anti-inflammatory property, however, little is known on its ability to bind at the binding site of TLR4/MD-2 complex of microglia as well as to be an antagonist for LPS. RESULTS: The present study reveals that both vitexin and donepezil are able to bind at the close proximity of LPS binding site located at the TLR4/MD-2 complex with the binding energy of − 4.35 and − 9.14 kcal/mol, respectively. During molecular dynamic simulations, both vitexin and donepezil formed stable complex with TLR4/MD-2 throughout the 100 ns time length with the root mean square deviation (RMSD) values of 2.5 Å and 4.0 Å, respectively. The root mean square fluctuation (RMSF) reveals that both compounds are stable. Interestingly, the radius of gyration (rGyr) for donepezil shows notable fluctuations when compare with vitexin. The MM-GBSA results showed that vitexin has higher binding energy in comparison with donepezil. CONCLUSIONS: Taken together, the findings suggest that vitexin is able to bind at the binding site of TLR4/MD-2 complex with more stability than donepezil throughout the course of 100 ns simulation. Hence, vitexin has the potential to be an antagonist candidate for LPS. BioMed Central 2021-06-05 /pmc/articles/PMC8178909/ /pubmed/34090414 http://dx.doi.org/10.1186/s12896-021-00697-4 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Yahaya, M. A. F.
Bakar, A. R. Abu
Stanslas, J.
Nordin, N.
Zainol, M.
Mehat, M. Z.
Insights from molecular docking and molecular dynamics on the potential of vitexin as an antagonist candidate against lipopolysaccharide (LPS) for microglial activation in neuroinflammation
title Insights from molecular docking and molecular dynamics on the potential of vitexin as an antagonist candidate against lipopolysaccharide (LPS) for microglial activation in neuroinflammation
title_full Insights from molecular docking and molecular dynamics on the potential of vitexin as an antagonist candidate against lipopolysaccharide (LPS) for microglial activation in neuroinflammation
title_fullStr Insights from molecular docking and molecular dynamics on the potential of vitexin as an antagonist candidate against lipopolysaccharide (LPS) for microglial activation in neuroinflammation
title_full_unstemmed Insights from molecular docking and molecular dynamics on the potential of vitexin as an antagonist candidate against lipopolysaccharide (LPS) for microglial activation in neuroinflammation
title_short Insights from molecular docking and molecular dynamics on the potential of vitexin as an antagonist candidate against lipopolysaccharide (LPS) for microglial activation in neuroinflammation
title_sort insights from molecular docking and molecular dynamics on the potential of vitexin as an antagonist candidate against lipopolysaccharide (lps) for microglial activation in neuroinflammation
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8178909/
https://www.ncbi.nlm.nih.gov/pubmed/34090414
http://dx.doi.org/10.1186/s12896-021-00697-4
work_keys_str_mv AT yahayamaf insightsfrommoleculardockingandmoleculardynamicsonthepotentialofvitexinasanantagonistcandidateagainstlipopolysaccharidelpsformicroglialactivationinneuroinflammation
AT bakararabu insightsfrommoleculardockingandmoleculardynamicsonthepotentialofvitexinasanantagonistcandidateagainstlipopolysaccharidelpsformicroglialactivationinneuroinflammation
AT stanslasj insightsfrommoleculardockingandmoleculardynamicsonthepotentialofvitexinasanantagonistcandidateagainstlipopolysaccharidelpsformicroglialactivationinneuroinflammation
AT nordinn insightsfrommoleculardockingandmoleculardynamicsonthepotentialofvitexinasanantagonistcandidateagainstlipopolysaccharidelpsformicroglialactivationinneuroinflammation
AT zainolm insightsfrommoleculardockingandmoleculardynamicsonthepotentialofvitexinasanantagonistcandidateagainstlipopolysaccharidelpsformicroglialactivationinneuroinflammation
AT mehatmz insightsfrommoleculardockingandmoleculardynamicsonthepotentialofvitexinasanantagonistcandidateagainstlipopolysaccharidelpsformicroglialactivationinneuroinflammation